CANDEL THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
CANDEL THERAPEUTICS, INC. (CADL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.65 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 421.31K shares, a 16.48% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.23M shares, a 37.74% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 98.60K shares.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 105.80K shares, a 403.81% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.19M shares, a 979.81% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 202.42K shares, a 84.59% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.31M shares, a 29.90% decline from fiscal 2022.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.87M shares, a 131.65% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 421.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 2.65M shares 10-Q · filed 2026-08-13 | 2.75M shares derived: sum of 3 quarters · filed 2026-08-13 | 2.86M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 2.23M shares 10-Q · filed 2026-05-14 | 2.33M shares derived: sum of 2 quarters · filed 2026-05-14 | 2.44M shares derived: sum of 3 quarters · filed 2026-05-14 | 2.80M shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 98.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 204.40K shares derived: sum of 2 quarters · filed 2026-03-12 | 566.10K shares derived: sum of 3 quarters · filed 2026-03-12 | 2.19M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 105.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 467.50K shares derived: sum of 2 quarters · filed 2025-11-13 | 2.09M shares 10-Q · filed 2025-11-13 | 2.09M shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 361.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 1.98M shares 10-Q · filed 2025-08-14 | 1.98M shares derived: sum of 3 quarters · filed 2025-08-14 | 2.00M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 1.62M shares 10-Q · filed 2025-05-13 | 1.62M shares derived: sum of 2 quarters · filed 2025-05-13 | 1.64M shares derived: sum of 3 quarters · filed 2025-05-13 | 1.75M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 21.00K shares derived: sum of 2 quarters · filed 2025-03-13 | 134.92K shares derived: sum of 3 quarters · filed 2025-03-13 | 202.42K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 21.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 134.92K shares derived: sum of 2 quarters · filed 2024-11-14 | 202.42K shares 10-Q · filed 2024-11-14 | 226.42K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 113.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 181.42K shares 10-Q · filed 2024-08-13 | 205.42K shares derived: sum of 3 quarters · filed 2024-08-13 | 246.02K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 67.50K shares 10-Q · filed 2024-05-14 | 91.50K shares derived: sum of 2 quarters · filed 2024-05-14 | 132.10K shares derived: sum of 3 quarters · filed 2024-05-14 | 1.32M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 24.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 64.60K shares derived: sum of 2 quarters · filed 2024-03-28 | 1.25M shares derived: sum of 3 quarters · filed 2024-03-28 | 1.31M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 40.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 1.23M shares derived: sum of 2 quarters · filed 2023-11-09 | 1.29M shares 10-Q · filed 2023-11-09 | 1.37M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 1.19M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.25M shares 10-Q · filed 2023-08-10 | 1.33M shares derived: sum of 3 quarters · filed 2023-08-10 | 1.90M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 61.00K shares 10-Q · filed 2023-05-11 | 143.50K shares derived: sum of 2 quarters · filed 2023-05-11 | 711.94K shares derived: sum of 3 quarters · filed 2023-05-11 | 889.94K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 82.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 650.94K shares derived: sum of 2 quarters · filed 2023-03-30 | 828.94K shares derived: sum of 3 quarters · filed 2023-03-30 | 1.87M shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 568.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 746.44K shares derived: sum of 2 quarters · filed 2022-11-10 | 1.79M shares 10-Q · filed 2022-11-10 | 1.88M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 178.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | 1.22M shares 10-Q · filed 2022-08-05 | 1.31M shares derived: sum of 3 quarters · filed 2022-08-05 | 1.40M shares derived: sum of 4 quarters · filed 2022-08-05 |
| 2022-03-31 | 1.04M shares 10-Q · filed 2022-05-12 | 1.13M shares derived: sum of 2 quarters · filed 2022-05-12 | 1.22M shares derived: sum of 3 quarters · filed 2022-05-12 | |
| 2021-12-31 | 88.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 176.08K shares derived: sum of 2 quarters · filed 2022-03-29 | 808.71K shares 10-K · filed 2022-03-29 | |
| 2021-09-30 | 87.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 720.21K shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 632.63K shares 10-Q · filed 2021-09-08 | |||
| 2020-12-31 | 3.22M shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |